Übersicht			Auf mobile öffnen

Lieferstatus:	Auf Bestellung (Lieferzeit unbekannt)
Veröffentlichung:	Januar 2007
Genre:	Wirtschaft / Recht
	Business and Management / C / Decision Making / Economic Theory / Economic theory & philosophy / Economic Theory/Quantitative Economics/Mathematical Methods / Economics, Mathematical / Finance / Finance & accounting / Finance, general / Financial Economics / Industrial Management / Innovation and Technology Management / Innovation/Technology Management / macroeconomics / Macroeconomics and Monetary Economics / Macroeconomics/Monetary Economics//Financial Economics / Management / Management decision making / Management science / Mathematics in Business, Economics and Finance / Monetary Economics / Operational research / Operations Research / Operations Research and Decision Theory / Operations Research/Decision Theory / Quantitative Economics / Quantitative Finance
ISBN:	9783540482635
EAN-Code:	9783540482635
Verlag:	Springer Nature EN
Einband:	Kartoniert
Sprache:	English
Dimensionen:	H 235 mm / B 155 mm / D
Gewicht:	910 gr
Seiten:	282
Illustration:	X, 282 p. 47 illus., schwarz-weiss Illustrationen
Bewertung:	Titel bewerten / Meinung schreiben

Inhalt:

Over the last years, due to intensive competition in the knowledge economy, legal aspects surrounding intellectual property (IP) rights - including litigation and settlement - have continuously gained in importance. Correspondingly, professional IP management has become an indispensable element of successful value-based management (VBM) in research-intensive firms. With this text, the author proposes an integrated approach to patent risk and capital budgeting in pharmaceutical research and development (R and D), developing an option-based view (OBV) of imperfect patent protection, which draws upon contingent-claims analysis, stochastic game theory, as well as novel numerical methods. Bridging a widening gap between recent advances in the theory of financial analysis and current challenges faced by pharmaceutical companies, the text re-initiates a discussion about the contribution of quantitative frameworks to value-based R and D management.